AstraZeneca PLC (AZN) FCF Payout Ratio: 54.45%
Is AstraZeneca PLC’s FCF payout ratio high or low?
AstraZeneca PLC's FCF payout ratio of 54.45% is 35% below its 5-year average of 83.45%, near the low end of its 5-year range (43.19%–162.88%).
1.95% above its 12-month average of 53.41%.
AZN FCF Payout Ratio Chart
AZN Average FCF Payout Ratio Chart
AZN Current vs Average FCF Payout Ratio Chart
AZN FCF Payout Ratio Metrics
FCF PAYOUT RATIO
54.45%
FCF PAYOUT RATIO AVG TTM
53.41%
FCF PAYOUT RATIO AVG 3Y
58.84%
FCF PAYOUT RATIO AVG 5Y
83.45%
FCF PAYOUT RATIO AVG 10Y
228.22%
FCF PAYOUT RATIO AVG 15Y
182.04%
FCF PAYOUT RATIO AVG 20Y
148.33%
CURRENT VS TTM AVG
+1.95%
CURRENT VS 3Y AVG
-7.46%
CURRENT VS 5Y AVG
-34.75%
CURRENT VS 10Y AVG
-76.14%
CURRENT VS 15Y AVG
-70.09%
CURRENT VS 20Y AVG
-63.29%
Payout Ratio Comparison
FCF Payout Ratio
54.5%
Earnings Payout Ratio
48.5%
Dividend Yield
1.76%
FCF Yield
3.20%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $11.77B | $5.08B | 43.2% |
| 2024 | $7.28B | $4.63B | 63.6% |
| 2023 | $6.57B | $4.48B | 68.2% |
| 2022 | $7.24B | $4.36B | 60.3% |
| 2021 | $3.76B | $3.86B | 102.5% |
| 2020 | $2.19B | $3.57B | 162.9% |
| 2019 | $509.00M | $3.59B | 705.7% |
| 2018 | $1.25B | $3.48B | 279.4% |
| 2017 | $1.96B | $3.52B | 179.7% |
| 2016 | $1.83B | $3.56B | 194.5% |
| 2015 | $536.00M | $3.49B | 650.4% |
| 2014 | $4.31B | $3.52B | 81.8% |
| 2013 | $5.34B | $3.46B | 64.8% |
| 2012 | $2.33B | $3.67B | 157.4% |
| 2011 | $6.52B | $3.76B | 57.7% |
| 2010 | $8.26B | $3.36B | 40.7% |
| 2009 | $8.78B | $2.98B | 33.9% |
| 2008 | $4.70B | $2.74B | 58.2% |
| 2007 | $5.83B | $2.64B | 45.3% |
| 2006 | $6.35B | $2.22B | 34.9% |
| 2005 | $5.76B | $1.72B | 29.8% |
| 2004 | $4.54B | $1.38B | 30.3% |
| 2003 | $2.13B | $1.22B | 57.3% |
| 2002 | $3.49B | $1.23B | 35.3% |
| 2001 | $443.83M | $0 | 0.0% |
| 2000 | $875.25M | $0 | 0.0% |
| 1999 | ($1.84B) | $0 | N/A (Loss) |
| 1998 | $34.86M | $0 | 0.0% |
| 1997 | ($8.27M) | $0 | N/A (Loss) |
| 1996 | $148.99M | $0 | 0.0% |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
AstraZeneca PLC FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC FCF Payout Ratio FAQ
- What is the FCF payout ratio for AstraZeneca PLC (AZN)?
- The FCF payout ratio for AZN stock is 54.45%.
- Is AstraZeneca PLC's FCF payout ratio high or low?
- AstraZeneca PLC's FCF payout ratio of 54.45% is 35% below its 5-year average of 83.45%, near the low end of its 5-year range (43.19%–162.88%).
- What is the TTM average FCF payout ratio for AstraZeneca PLC (AZN)?
- The TTM average FCF payout ratio for AZN stock is 53.41%.
- What is the 3Y average FCF payout ratio for AstraZeneca PLC (AZN)?
- The 3Y average FCF payout ratio for AZN stock is 58.84%.
- What is the 5Y average FCF payout ratio for AstraZeneca PLC (AZN)?
- The 5Y average FCF payout ratio for AZN stock is 83.45%.
- What is the 10Y average FCF payout ratio for AstraZeneca PLC (AZN)?
- The 10Y average FCF payout ratio for AZN stock is 228.22%.
- What is the 15Y average FCF payout ratio for AstraZeneca PLC (AZN)?
- The 15Y average FCF payout ratio for AZN stock is 182.04%.
- What is the 20Y average FCF payout ratio for AstraZeneca PLC (AZN)?
- The 20Y average FCF payout ratio for AZN stock is 148.33%.
AstraZeneca PLC FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2025-12-31 | 43.19% |
| 2024-12-31 | 63.63% |
| 2023-12-31 | 68.24% |
| 2022-12-31 | 60.30% |
| 2021-12-31 | 102.47% |
| 2020-12-31 | 162.88% |
| 2019-12-31 | 705.70% |
| 2018-12-31 | 279.39% |
| 2017-12-31 | 179.72% |
| 2016-12-31 | 194.48% |
| 2015-12-31 | 650.37% |
| 2014-12-31 | 81.77% |
| 2013-12-31 | 64.79% |
| 2012-12-31 | 157.36% |
| 2011-12-31 | 57.69% |
| 2010-12-31 | 40.69% |
| 2009-12-31 | 33.90% |
| 2008-12-31 | 58.24% |
| 2007-12-31 | 45.29% |
| 2006-12-31 | 34.94% |
| 2005-12-31 | 29.79% |
| 2004-12-31 | 30.35% |
| 2003-12-31 | 57.26% |
| 2002-12-31 | 35.35% |
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot